Scholars Central

Conference abstractPublished 30 Jun 2016

A rare case of mixed neuroendocrine tumor and adenocarcinoma of the pancreas

Authors: Sofia Xenaki, Konstantinos Lasithiotakis, Anna Daskalaki, Maria Tzardi, Emmanuel Chrysos, George Chalkiadakis

University Hospital of Heraklion, Greece

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Neuroendocrine carcinoma (NEC) of the pancreas is a rare tumor with aggressive progression and poor prognosis. ItâÂ?Â?s coexistence with adenocarcinoma poses significant clinical problems and has not been addressed in the literature. Herein, we describe a case of a 51 year old male who underwent pancreatoduedonectomy for a pancreatic head tumor 1.5Ã?Â?1Ã?Â?1.4 cm. Histological examination of the specimen revealed a mixed neoplasm: A well differentiated Cytokeratin 7 (+), Cytokeratin 20 (+), CEA (+) adenocarcinoma, neoplastic blasts of which are extended focally to the submucosa without invading the muscular layer and a low differentiated NEC consisting of solid clusters and pagetoid formations. The neoplastic cells of the former tumor are homogenous without obvious cytoplasm and a high number of mitoses. Immunohistochemical staining showed that the latter tumor was Cytokeratin 7 (-), Cytokeratin 20 (-), CEA (-), Cytokeratin MNF 116 (+), CD56 (+), NSE (+), Synaptophysin (+), Chromogranin (-). Carcinomatous lymph embolus was obvious as well but all 18 lymph nodes of the specimen were free of neoplastic disease and the surgical margins of the specimen were tumor free. Two months after the operation the patient developed liver metastasis. Ocreoscan revealed a region with moderate scintillation in the left hepatic lobe. FNA cytology of the hepatic lesions revealed low grade carcinoma with neuroendocrine characteristics and the patients received first line chemotherapy treatment with VP and CDDP. After 2 months CT of the abdomen showed progressive disease (PD) and received 2nd line chemotherapy with paclitaxel, ifosfamide, Mesna and CDDP. Three months later due to PD the patient received 3rd line treatment with Folfox and Avastin but he did not responded and after two months received Folfiri and Avastin, four months later again the patient had PD and received 5th line treatment with CAV. The patient experienced grade four myelotoxicity without evidence of any response to chemotherapy and denied further treatment. He was discharged from the hospital and succumbed to his disease 13 months after the operation. Co-existence of NEC with adenocarcinoma of the pancreas is a very rare entity, may be resistant to various chemotherapeutic regimens and have very poor prognosis.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical Case Reports.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical Case Reports
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Sofia Xenaki”
  • BylineArticles whose byline prints “Konstantinos Lasithiotakis”
  • BylineArticles whose byline prints “Anna Daskalaki”
  • BylineArticles whose byline prints “Maria Tzardi”
  • BylineArticles whose byline prints “Emmanuel Chrysos”
  • BylineArticles whose byline prints “George Chalkiadakis”